PubMed Health⌕ Search

Biomedical subjects

W Samtleben

Publications and source records attributed to W Samtleben.

95 records · Page 6Linked to original sources
PubMedDate not supplied

Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.

Recently CYFRA 21-1, a new tumor marker measuring a fragment of cytokeratin 19, was introduced and proved to be suitable for therapy monitoring and follow-up of non-small cell lung carcinomas (NSCLC), in particular squamous cell carcinomas. Besides CYFRA 21-1 there are two other tumor markers, tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS), which also measure various cytokeratins in serum. In a retrospective study we investigated the clinical significance of these three cytokeratin markers in lung cancer and in carcinoma of the urinary bladder. For this purpose we investigated the sera of 50 healthy persons, 273 patients with various benign diseases, 218 patients with histologically proven lung cancer and 88 patients with carcinoma of the urinary bladder. In a first step the specificity was established for the different reference groups and the cutoff values were fixed at a specificity of 95%. In lung cancer the single and combined sensitivities were calculated versus benign lung diseases (n = 58) as reference group. With single determinations CYFRA 21-1 proved to have the highest sensitivity in lung cancer in general (61%), in non-small cell lung carcinomas (64%), in squamous cell carcinomas (79%), in adenocarcinomas (54%) and in large cell carcinomas (65%). In small cell lung carcinomas (SCLC) NSE was confirmed to be the marker of choice (55%). With combined determinations a clear increase in sensitivity could only be reached in large cell carcinomas (CYFRA 21-1 + TPA: 77%) and in small cell carcinomas (CYFRA 21-1 + NSE: 62%).(ABSTRACT TRUNCATED AT 250 WORDS)

Automation↗
PubMedDate not supplied

Apheresis without substitution fluid: devices, directions and limitations.

Significant economic and medical drawbacks attend the requirement for infusion of large quantities of exogenous substitution fluid during therapeutic plasma exchange. A variety of physicochemical processes are available for the fractionation of plasma (ultrafiltration, fractional precipitation, adsorption, electrophoresis, selective enzymatic degradation) and we review here their application to 'closed loop' apheresis, a format in which the patient's own plasma is returned after the pathogenic species are removed. The different separation processes vary significantly in their method of action, their specificity, and their status of development. Disposables and hardware for two specific protocols, cascade filtration and cryofiltration, are already commercially available and appropriate for routine clinical use in limited subsets of diseases considered treatable by therapeutic apheresis.

Adsorption↗